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Background: Patients with B cell malignancies refractory to allogeneic stem cell transplantation (SCT) can be treated
by subsequent immunotherapy with donor lymphocyte infusions (DLI). But unlike myeloid leukemia, B cell leukemia
and lymphoma are less sensitive to allogeneic adoptive immunotherapy. Moreover, the beneficial graft-versus-lymphoma
(GVL) effect may be associated with moderate to severe graft-versus-host disease (GVHD). Thus, novel therapeutic
approaches augmenting the anti-tumor efficacy of DLI and dissociating the GVL effect from GVHD are needed. The
anti-CD20 x anti-CD3 trifunctional bispecific antibody (trAb) FBTA05 may improve the targeting of tumor cells by
redirecting immune allogeneic effector cells while reducing the risk of undesirable reactivity against normal host cells.
Hence, FBTA05 may maximize GVL effects by simultaneously decreasing the incidence and severity of GVHD.
Methods/Design: Based on this underlying treatment concept and on promising data taken from preclinical results and
a small pilot study, an open-label, non-randomized, uncontrolled, dose-escalating phase I/II-study is conducted to
evaluate safety and preliminary efficacy of the investigational antibody FBTA05 in combination with DLI for patients
suffering from rituximab- and/or alemtuzumab-refractory, CD20-positive low- or high-grade lymphoma after allogeneic
SCT. During the first trial phase with emphasis on dose escalation a maximum of 24 patients distributed into 4 cohorts
will be enrolled. For the evaluation of preliminary efficacy data a maximum of 12 patients
(6 patients with low-grade lymphoma and/or Chronic Lymphocytic Leukemia (CLL) / 6 patients with high-grade or
aggressive lymphoma) will attend the second phase of this clinical trial.
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Discussion: Promising data (e.g. induction of cellular immunity; GVL predominance over GVHD; achievement of partial or
complete responses; prolongation of time-to-progression) obtained from this phase I/II trial would represent the first
milestone in the clinical evaluation of a novel immunotherapeutic concept for treatment-resistant low- and high-grade
lymphoma and NHL patients in relapse.
Trial registration: NCT01138579
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Trifunctional Bispecific Antibody (trAb)Background
B cell malignancies
Approximately half of the patients with aggressive non-
Hodgkin's lymphomas (NHL) and the majority of pa-
tients with low-grade lymphomas cannot be cured by
conventional therapeutic treatment regimes. Intensive
chemotherapy followed by stem cell support has im-
proved survival of patients with chemotherapy sensitive
lymphoma. The majority of these patients, however, will
still relapse, even after high-dose therapy and subse-
quently have limited therapeutic options. Although allo-
geneic stem cell transplantation (allo-SCT) can induce
long-term remission due to a graft versus lymphoma
(GVL) reaction, this occurs predominantly in a highly
selected population of indolent lymphoma patients. A
GVL reaction is less pronounced in patients with aggres-
sive lymphoma, resulting in a high relapse rate [1-7]. In
patients not eligible for allogeneic stem cell transplant-
ation, palliative treatment is restricted by resistance to
chemotherapy and complications of infection. Therefore,
new therapeutic strategies with improved anti-tumor ef-
ficacy need to be developed for such patients.
Immunotherapies with monoclonal antibodies (mABs)
directed against the CD20 antigen have previously been
shown to be highly effective. Rituximab (Rituxan;
Genentech Inc, South San Francisco, CA, and Biogen
IDEC Inc, Cambridge, MA), an immunoglobulin gamma
(IgG) 1 chimeric mAb, induced overall response rates
(ORR) up to 50% in patients with relapsed or refractory
low-grade B cell lymphoma [8,9]. In first line-treatment,
rituximab induces response rates up to 75% in patients
with follicular or low-grade NHL [10]. But despite these
encouraging results, there are still numerous patients
who do not respond or finally relapse [11].
Efforts to further increase the therapeutic efficacy of
antibodies resulted in the development of trAb FBTA05
which mediates effective tumor cell cytotoxicity even at
low CD20 expression levels, and probably even more im-
portantly, induces a lasting anti-tumor immunity [12-15].
Compound review
FBTA05 is a heterologous antibody, composed of two
potent heavy chain subclasses, a mouse IgG2a and a ratIgG2b chain, each with their respective light chains. It
therefore possesses two specific and one functional bind-
ing site. FBTA05 binds with one binding arm to the CD3
antigen on T cells and with the second binding arm to
the CD20 antigen, which is expressed exclusively on nor-
mal and malignant B cells, but not on hematological
precursor cells or other human cell types. In addition,
the third functional site within the hybrid Fc region
binds to Fcγ receptor type I, IIa and III which are
expressed by accessory cells (e.g., macrophages, dendritic
cells, natural killer cells) of the immune system. In this
“tri-cell complex”, an important “crosstalk” between T
cells and accessory cells can occur, which includes co-
stimulatory signals necessary for a physiological T cell
activation cascade. The simultaneous activation of differ-
ent immune cells at the tumor site results in efficient
killing of tumor cells by several complementary mecha-
nisms (e.g. release of cytokines, perforin-mediated lysis
and phagocytosis). The antibody-mediated phagocytosis
of tumor cells by accessory cells (macrophages and den-
dritic cells) is believed to result in the processing of
tumor antigens and presentation on the surface of these
cells. Since this can result in polyclonal humoral and cel-
lular immune responses [13,14], a T cell response even
against unknown, tumor-associated peptides may be
induced.
The combined attack of various immune cells with dif-
ferent killing mechanisms induced by FBTA05 leads to a
significant tumor cell elimination when compared to
monospecific antibodies or conventional bispecific anti-
bodies. In addition, the induction of a variety of effector
mechanisms may result in a protective long-term anti-
tumor immunity. The postulated mechanism of action
of the trAb FBTA05 is shown in Figure 1.
Previous trials and clinical data
Prior to the start of the current phase I/II dose escalat-
ing study, FBTA05 was administered in a compassionate
use setting to patients with recurrent and refractory B
cell malignancies following allo-SCT, and within a phase
I/II trial (IV-A05-LL-01, EudraCT No: 2006-006694-24)
to patients with relapsed or refractory CLL in an autolo-
gous setting.
Figure 1 FBTA05 (anti-CD3 x anti-CD20 trAb) – mode of action. In a MHC-independent manner polyclonal T cells are redirected to and
activated at tumor cells by trAb-mediated recognition of CD3 and tumor-associated antigens (TAAs) such as CD20. At the same time or subsequently
FcγR-positive accessory cells such as monocytes/macrophages, dendritic cells (DCs) or natural killer cells interact with the Fc part of trAbs. Through this
cellular crosstalk all participating immune cells are strongly activated. Hence, T cells receive a second co-stimulatory signal, while accessory immune
cells are stimulated via FcγR crosslinking which leads to the release of proinflammatory cytokines. Thus, tumor cells are effectively eliminated by a
concerted attack of cytotoxic T cells and accessory immune cells using different killer mechanisms such as ADCC, phagocytosis, or perforin/
granzyme-mediated lysis and apoptosis induction. Finally, T cell proliferation occurs as does phagocytosis of necrotic/apoptotic tumor particles which
are then processed, and presented by stimulated professional antigen presenting cells (i.e. DCs), an important prerequisite for the induction of
long-lasting vaccination-like effects against tumors. ADCC (antibody dependent cellular cytotoxicity); CMC (complement-mediated cytotoxicity);
DC-CK1 (Dendritic cell cytokine 1); IL (interleukin); LFA (leukocyte function-associated antigen); TNF-α (Tumor necrosis factor α).
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cancer patients were treated with FBTA05. These, in-
cluded 4 patients with refractory Chronic Lymphocytic
Leukemia (CLL), 4 patients with refractory high-grade
non-Hodgkin Lymphoma (HG-NHL) and 1 patient with
refractory Acute Lymphocytic Leukemia (ALL) [16]. The
treatment comprised escalating doses of FBTA05 with a
range of 10–2,000 μg per single infusion. The maximum
cumulative dosage administered per patient ranged be-
tween 130–13,610 μg of FBTA05. The duration of treat-
ment was between 5–76 days. Following FBTA05
treatment, patients received DLI. Due to the nature of
the different indications, the number of peripheral B
cells prior to the start of FBTA05 infusions showed a
large variation. An anti-tumor response (decrease of
leukemic cells and shrinking of lymph nodes) was ob-
served in 3 of 4 CLL patients. In 1 case of HG-NHL, a
halt of progression for almost 4 months was observed.
The effect of FBTA05 in the other patients was not
evaluable due to other concomitant treatment or disease
(fungal infection). Relapse finally occurred in all patients.
The main side effects were restricted to fever, chills, bone
pain and transient increase in γ-glutamyl transpeptidase(γGT). Only one case of GVHD (grade 3) was observed
after FBTA05 and DLI and this was in the ALL patient. In
context of the administration of the highest cumulative
dose of FBTA05 (6,240 μg), a transient granulocytopenia
was detected in a HG-NHL patient. The cytokine profile
was characterized by a transient increase of IL-6, IL-8 and
IL-10. Human anti-mouse antibodies (HAMAs) were not
detectable. According to the current experience with the
anti HER2/neu directed trAb ertumaxomab there is a cor-
relation between the formation of HAMA and human
anti-rat antibodies (HARAs), so HARA development in
these patients would seem to be unlikely [17].
Due to the changes in the development program of
the sponsor (Fresenius Biotech GmbH) the phase I/II
dose escalating study (IV-A05-LL-01, EudraCT No:
2006-006694-24) was prematurely terminated after treat-
ment of 3 patients in the first cohort (maximum dose
100 μg FBTA05). Thus, no maximum tolerated dose
(MTD) could be established and only limited data on
drug safety are available. In general, the intravenous in-
fusion of FBTA05 was assessed to be safe and well toler-
ated, even at higher antibody doses. However, due to the
limited number of patients treated, to variable disease
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ferent concomitant treatments used, this information
needs to be interpreted with caution.
Rationale for performing the study
Antibody based therapies (rituximab, alemtuzumab), es-
pecially in combination with chemotherapeutic regimes,
offer some advantages in patients with CLL and B cell
non-Hodgkin lymphoma (NHL). Nevertheless, most pa-
tients finally relapse. Especially patients with diffuse
large B cell lymphoma (DLBCL) have a very poor prog-
nosis in case of early relapse after chemotherapy com-
bined with rituximab. Therefore, there is an urgent need
to further develop alternative treatment options whereby
the CD20 antigen represents a solid target for innovative
therapeutic approaches: (i) it is expressed on most B-cell
lymphomas, (ii) it is only expressed on B cells, but not
precursor cells or human tissues and (iii) it is not shed
or secreted upon antibody binding.
The trAb FBTA05 provides a novel and unique ap-
proach for the targeted treatment of CD20 expressing
neoplasias. The potency of FBTA05 has been demon-
strated by efficient in vitro killing of human B cell tumor
cells, as well as cells derived from CLL patients express-
ing only low levels of CD20 [12]. FBTA05 in combin-
ation with DLI has already been administered to patients
in compassionate use prior to the start of the scheduled
phase I/II study and assessed to be feasible, safe and well
tolerated even at high antibody and T cell doses. Most
importantly, some anti-tumor responses were observed
in 3 CLL and 1 NHL patient [16].
It is well established that DLI, given as a single treat-
ment is effective in hematological relapse post-SCT, but
it is suggested that concerted treatment with additional
drugs may further improve treatment outcome [18,19].
Thus, the combination of DLI and the anti-CD20 x anti-
CD3 trAb FBTA05 might be a promising treatment op-
tion for patients with B cell malignancies refractory to
allo-SCT. Since both, the desired GVL and the un-
wanted detrimental GVHD responses are mediated by T
lymphocytes present in DLI preparations, FBTA05 has
the capacity to enhance these GVL effects as autologous
and allogeneic T cells are targeted to tumor sites. At the
same time as GVL of allogeneic T lymphocytes is
strengthened by FBTA05 engagement the risks for
GVHD development are reduced. Therefore, by adding
FBTA05 to the established allogeneic DLI treatment re-
gime patients may even benefit more from this com-
bined therapeutic approach. Furthermore, FBTA05 should
be given prior to DLI administration to allow the already
bound anti-CD20 x anti-CD3 trAbs FBTA05 to attract
incoming allogeneic T lymphocytes directly to the CD20-
expressing tumor cells. In other words, this treatment
setting may favor GVL enhancement by simultaneouslyminimizing GVHD risks. This application sequence may
be also important to control cytokine release due the
increased number of CD3+ T target cells of FBTA05
in the blood circulation after DLI infusion. The opposite
application order for FBTA05 and DLI would not mediate
this positive effect of pre-coating tumor cells with trAb
FBTA05 in vivo for attracting incoming allogeneic T lym-
phocytes. Moreover, preclinical and first clinical data con-
firmed this beneficial sequence for FBTA05 and DLI
application.Methods/design
The present trial is an investigator-initiated, open-
label, multi-center, non-randomized, uncontrolled, dose-
escalating phase I/II study designed to evaluate the safety
and efficacy of the investigational trAb FBTA05 in com-
bination with DLI for treatment of relapsed or refractory
disease in CD20 positive CLL / low-grade NHL or high-
grade NHL after allogeneic transplantation.Primary and secondary objectives
The primary objective is the determination of the MTD
of FBTA05 in phase I (dose-escalation part). In phase II
(efficacy part), it is the preliminary evaluation of efficacy
of a treatment schedule with FBTA05 and DLI in pa-
tients with CD20 positive either CLL / low-grade NHL
or high-grade NHL after allo-SCT. The secondary objec-
tives are the evaluation of safety and pharmacodynamics
of FBTA05 in combination with DLI, the induction of
cellular immunity in terms of GVL or GVHD, and the
determination of further efficacy data in terms of time to
progression (TTP), duration of response and clinical
benefit.Primary and secondary endpoints
The primary endpoint in Phase I is the incidence of dose
limiting toxicities (DLTs), in phase II the objective re-
sponse rate. The secondary endpoints are safety and effi-
cacy. Regarding safety, the recommended dose of FBTA05
in combination with DLI for further efficacy studies will
be determined. Furthermore, the incidence of adverse
events (AEs), the presence of HAMAs after FBTA05 ap-
plication, the need to discontinue FBTA05 infusion, vital
functions, the physical examination findings, laboratory
parameters, concomitant medication and as pharmacody-
namic endpoints the serum levels of cytokines will be
recorded.
In terms of efficacy the clinical benefit rate, the dur-
ation of response, the time to progression, the overall
survival, the ECOG performance status, the tumor spe-
cific response, lymphocyte subsets, activation signs and
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FBTA05 FBTA05 FBTA05 FBTA05 
d14 d21 d28 d35
DLI
Course II  
FBTA05 FBTA05 FBTA05 FBTA05 
d42 d49 d56 d63
DLI
Figure 2 Treatment schedule. The FBTA05 treatment schedule consists of three parts: the drug induction part (safety part) and the dose
maintenance / escalation parts (course I / II). Thereby the safety part is the same for each study patient, with FBTA05 applications of 10 μg on day
0, 20 μg on day 3 and 50 μg on day 7. FBTA05 dose adjustment for the subsequent treatment courses I and II, will be performed according to
the respective cohort A-D (Table 1). Infusion of donor lymphocytes (DLI) will be dose-escalated (Table 3) and applied subsequent to the
respective antibody infusions on day 7, day 35 and day 63 of the treatment schedule. The red arrows indicate the application of FBTA05, the
green arrows the infusion of donor lymphocytes.
Table 1 Dose escalation of FBTA05
FBT05 Day Cohort A Cohort B Cohort C Cohort D
Safety part d0 10 μg 10 μg 10 μg 10 μg
d3 20 μg 20 μg 20 μg 20 μg
d7 50 μg 50 μg 100 μg 200 μg
FBT05 Day Cohort A Cohort B Cohort C Cohort D
Course I d14 50 μg 50 μg 100 μg 200 μg
d21 50 μg 50 μg 100 μg 200 μg
d28 50 μg 50 μg 100 μg 200 μg
d35 50 μg 100 μg 200 μg 300 μg
Course II d42 50 μg 100 μg 200 μg 300 μg
d49 50 μg 100 μg 200 μg 300 μg
d56 50 μg 100 μg 200 μg 300 μg
d63 50 μg 100 μg 200 μg 300 μg
FBTA05 (anti-CD3 x anti-CD20 trAb).
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To evaluate differences in drug response to CLL/low
grade NHL or high grade NHL, patients are enrolled
into study cohorts according to their respective disease
entity (either CLL / low-grade NHL or high-grade
NHL). As shown in Figure 2, the complete treatment
course consists of a drug induction part (safety part)
with defined FBTA05 doses of 10 μg on day 0, 20 μg on
day 3 and 50 μg on day 7, as well as a drug maintenance /
escalation part (course I and II, see also Table 1). The final
antibody infusion of each part is followed by a dose-
escalated application of donor lymphocytes.
Each cohort includes at least 2 patients. In a strict se-
quential order, treatment and dose escalation (cohort A-D,
Table 1) is performed independently for each disease entity
(either CLL / low-grade NHL or high-grade NHL). Thus,
treatment of any subsequent patient 2 or 3 at a certain
dose level will be started only after the safety part treat-
ment of the previous patient of the same disease entity is
completed, and the External Safety Board (ESB), acting as
a Dose Steering Board (DSB), agrees to the enrolment of
the next patient. The same dose escalation procedure will
be applied throughout the study for all Cohorts (A-D). If
one dose-limiting toxicity is seen, a total of 3 patients of
the same disease entity must be treated at that dose level.
If two dose-limiting toxicities are seen at any dose level,
treatment for this disease entity is terminated and the
MTD will be established at the next lower dosing level. If
2 of 3 patients of the same disease entity in Cohort A showdose-limiting toxicities, the MTD has been reached and
lower dose levels may have to be investigated.
After the phase I part of the study an interim analysis
will be performed. Based on the outcome of this analysis
the recommended dose (RD) for the phase II part will be
proposed by the ESB and the investigators on the basis
of the MTD and any other relevant safety issues. The
recommended dose will not exceed the maximal dose
foreseen in the protocol approved by the competent au-
thority. The report of the interim analysis with the
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mittee and competent authority. A maximum of 6 pa-
tients per disease entity will receive treatment during
phase II. If the last Cohort at MTD level in phase I
already included 2 or 3 patients for CLL/low grade
NHL, respectively high-grade NHL, an additional 4 or 3
patients per disease entity will be enrolled in phase II.
Number of patients and eligibility criteria
There will be a maximum of 24 patients in the MTD
evaluation part of phase I: 12 patients for CLL / low-
grade NHL, 12 patients for high-grade NHL. There will
be a maximum of 12 patients in phase II of the study: 6
patients for CLL / low-grade NHL, 6 patients for HG-
NHL. A total of maximal 30 patients will be included in
the study.
Patients of both genders, any ethnic origin and at least
18 years old are included in the study if they meet the
criteria given in Table 2. All participating patients have
to sign the written informed consent. Patients can be
withdrawn from the study for medical reasons at any
time and must be withdrawn in the event of a dose-
limiting toxicity. Patients can recall their consent at any
time without any negative implications for their further
treatment.
Drug formulation
The investigational drug FBTA05 is provided by the
TRION Pharma GmbH (Munich, Germany) as a sterile,Table 2 Eligibility criteria of the FBTA05 trial
Inclusion
criteria
- confirmed CLL, low-grade NHL or high-grade NHL
- CD20 positivity
- relapsed or refractory disease > 60 days after allogeneic
transplantation
- adequate hematological, liver and kidney functions
- platelet count ≥ 25 G/l
- ECOG performance status ≤ 2
- negative pregnancy test (adequate contraception during
study in women of child bearing potential)
Exclusion
criteria
- anti-CD20 or anti-T cell antibody treatment < 3 months
before FBTA05 treatment
- positivity for human anti-mouse antibodies
- history of GVHD °III or °IV, or GVHD requiring steroid
therapy with ≥ 10 mg / day
- known hypersensitivity to recombinant murine or
rat proteins
- acute or uncontrolled chronic infections, viral infections
at risk of reactivation (e.g. HCV, HBV, HIV)
- patients unable or unwilling to comply fully with
the protocol
CLL chronic lymphocytic leukemia, NHL Non-Hodgkin's lymphoma, ECOG
Eastern Cooperative Oncology Group, HAMA human anti-mouse antibody,
GVHD graft versus host disease, HCV hepatitis C virus, HBV hepatitis B virus,
HIV human immunodeficiency virus.pyrogen-free, color-free and preservative-free solution
for infusion. The concentrate contains 0.2 mg/ml anti-
body per 100mM sodium citrate buffer (pH 5.6), with
0.02% Tween 80. Depending on the dose level, FBTA05 is
further diluted in 0.9% sodium chloride solution for i.v.
infusion.
Study treatment
FBTA05 is administered with a constant rate over 6
hours by intravenous (i.v.) infusion. To avoid infusion
reactions typically occurring after i.v. antibody infusions,
i.v. Paracetamol (1,000 mg) and i.v. Dimetinden (4 mg)
are administered 30–60 minutes prior to the start of in-
fusion. Three hours after the start of FBTA05 infusion, i.v.
Paracetamol (500 – 1,000 mg) is repeated. Post-infusion,
Paracetamol and Dimetinden are administered, as needed.
In phase I, each patient (cohort A – D) will undergo
the same safety part and receive induction doses of
FBTA05 on day 0 (10 μg), day 3 (20 μg) and day 7 (50
μg). During the maintenance part, FBTA05 applications
are scheduled for course I on day 14 (± 1 day), 21 (± 1
day), 28 (± 1 day) and 35 (± 1 day), for course II on day
42 (± 1 day), 49(± 1 day), 56 (± 1 day) and 63 (± 1 day).
Thereby dose escalation of FBTA05 will be performed
according to the respective Cohort A – D (Table 1).
Donor lymphocyte infusion is scheduled in each co-
hort at the end of the safety part (day 7), as well as at
the end of course I (day 35) and course II (day 63). The
numbers of infused T cells are escalated according to the
respective preparative regimen applied for allo-SCT as
shown in Table 3. DLI will not be performed in case the
of GVHD or active infection at the time of DLI, or in
the rare cases that DLI is not available for technical rea-
sons. In this case antibody application will be continued
as scheduled without DLI.
In phase II the recommended dose will be applied
according to the respective treatment schedule as deter-
mined in phase I.
Study visits
Patients are required to complete screening procedures
and 14 treatment visits (11 applications of FBTA05; 3 ap-
plications of DLI), so far as the dosage regimen is tolerated
according to MTD assessments. Two weeks after the last
infusion (week 12), patients will attend an end-of-studyTable 3 Dose escalation of donor lymphocyte
infusions (DLI)
DLI Haplo-identical SCT HLA-identical SCT
d7 5 ×105 /kg CD3+ cells 1 ×106 /kg CD3+ cells
d35 1 ×106 /kg CD3+ cells 5 ×106/kg CD3+ cells
d63 5 ×106 /kg CD3+ cells 1 ×107/kg CD3+ cells
SCT stem cell transplantation, HLA human leukocyte antigen.
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post-study follow-up visits (6, 9, 12 and 24 months after
start of treatment). Patients enrolled in phase II will follow
the identical screening, treatment and post-study follow-
up schedule as for phase I.
Safety management
An ESB, composed of three independent experienced
clinical experts is responsible for the evaluation of the
patients. Together with the investigators they decide,
whether individual patients may continue the study, and
whether or not dose escalation can be applied. The ESB
is involved in the assessment and declaration of Serious
Adverse Events (SAEs), Suspected Unexpected Serious
Adverse Reactions (SUSARs) as well as the evaluation of
dose-limiting toxicities (DLT). Moreover, based on the
results of the interim analysis at the end of the phase I,
the ESB together with the investigators will propose the
recommended dose (RD) for phase II.
The condition for a DLT is fulfilled in the case of ter-
mination of treatment due to an adverse reaction.
Thereby, the treatment schedule for a patient must be
terminated if any toxicity grade ≥ 3, condition or adverse
event (e.g. body temperature ≥ Grade 3 Common Tox-
icity Criteria (CTC) (40°C), systolic BP < 75 or > 210
mm Hg, pulse < 50 or > 150 bpm or a dyspnoea grade
IV) does not normalize within 3 hours. Furthermore,
treatment will be terminated in case of an anaphylactic re-
action, including, but not limited to severe angioedema,
severe bronchospasm, severe urticaria or anaphylactic
shock which occurs during the infusion. An adverse reac-
tion, including clinical conditions of CTC Grade ≥ 3 or
clinically relevant laboratory abnormality of CTC Grade ≥
3 which occurs after the infusion and does not resolve
until the planned date of the next infusion will also be
grounds for termination of treatment.
Safety, laboratory and imaging assessments
To assure the safety of the study patients a substantial
examination program is performed. The patients are
under hospital surveillance at least 1 hour prior to infu-
sion and for 24 hours after the start of infusion. Physical
examinations are performed at all scheduled visits and
vital parameters (e.g. blood pressure, pulse rate, respira-
tory rate, oxygen-saturation and body temperature) are
monitored throughout the infusion time until 24 hours
after start of infusion. Moreover, patients are evaluated
with regard to clinical signs, symptoms (including AEs)
and subjective well-being.
Laboratory parameters for safety analysis and immune
monitoring are evaluated at every study visit. Moreover,
during treatment, blood will be drawn prior to the start
of infusion, at the end of the 6-hour drug infusion
period and at 24 after the start of infusion. Bloodchemistry parameters include sodium, potassium, cal-
cium, chloride, bilirubin (total), aspartate aminotransfer-
ase (AST, or SGOT), alanine aminotransferase (ALT, or
SGPT) gamma-glutamyltransferase (GGT), alkaline phos-
phastase, antithrombin III, albumin, creatinine, uric acid,
lactate dehydrogenase, partial thromboplastin time (PTT),
quick prothrombin time, fibrinogen and the C-reactive
protein (CRP). Hematology parameters encompass he-
matocrit, hemoglobin (Hb), red blood cell (RBC) count,
white blood cell (WBC) count, reticulocytes, platelets and
differential WBC. An extensive immune monitoring pro-
gram determines lymphocyte subsets (CD4, CD8 T cells, B
cells, NK cells, monocytes) including effector, central
memory as well as regulatory T cells and cytokine release
profiles comprising interleukin-2 (IL-2), IL-4, IL-6, IL-8,
IL-10, interferon-gamma (IFN-γ), and tumor necrosis
factor-alpha (TNF-α). Experimental ELISPOT-analysis to
evaluate the induction of tumor specific immune re-
sponses after treatment with FBTA05 is restricted to CLL
samples.
Bone marrow biopsies are done before the start of
treatment, moreover at the EOS and, 12 and 24 months
after the start of therapy. Disseminated tumor cells will
be determined by analyzing bone marrow aspirates taken
from the iliac crest. Changes in the presence of dissemi-
nated tumor cells in the bone marrow will be assessed
according to NCI criteria.
Tumor assessment via imaging techniques (sonog-
raphy, compute tomography, magnetic resonance tom-
ography or positron-emission tomography) is clinical
practise for the advanced stage of disease and will be
performed at the screening, end of study visit and follow
up visits scheduled 6, 9, 12 and 24 month after onset of
the study. Assessment will be done according to Re-
sponse Evaluation Criteria in Solid Tumors (RECIST).
Statistics
The study is exploratory and is not powered to address
any predefined hypotheses. The safety analysis will be
performed on the safety analysis set, which includes all
patients who received at least one FBTA05 infusion. The
efficacy analysis will be performed on both the safety
analysis set, which includes all patients who received at
least the first three infusions and the first DLI (safety
part). Efficacy endpoints will be analyzed by use of ap-
propriate descriptive techniques.
Trial organization and administration
Funding
The FBTA05 trial is supported by the Bavarian Im-
munotherapy Network (BayImmuNet) and the Munich
m4-Biotech Cluster. BayImmunet is funded by the
Bavarian State Ministry of Sciences, Research and the
Arts (Bayerisches Staatsministerium für Wissenschaft,
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Munich m4-Biotech Cluster is supported by the German
Ministry of Research and Education (Bundesministerium
für Bildung und Forschung (BMBF); 01EX1021A). The in-
vestigational drug FBTA05 used in the present trial is pro-
vided by Trion Pharma GmbH (Munich, Germany). No
financial support is given other than the funding men-
tioned above. There are no restrictions on publications.
Industrial funders and trial management are independent.
Sponsor
Klinikum rechts der Isar (RdI), Technische Universitaet
Muenchen (TUM).
Study approval
Before start of the trial, the trial protocol, informed con-
sent document and any other trial documents were sub-
mitted to the independent ethics committee and the
regulatory authority (Paul-Ehrlich-Institute, PEI). Ethics
approval was granted on 14 January 2010, PEI approval
on 16 July 2010.
Registration
The trial protocol was registered at http://www.clinical
trials.gov and was given the number NCT01138579.
Good clinical practice
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation and documentation of this
trial, are designed to ensure that all persons involved in
the trial abide by Good Clinical Practice [20] and the
ethical principles described in the current revision of the
Declaration of Helsinki [21]. The trial will be carried out
in keeping with local legal and regulatory requirements.
Discussion
The idea to redirect immunity via bispecific antibodies is
currently one of the most compelling concepts in cancer
treatment. In the meantime, various bispecific antibody
formats have entered clinical trials indicating their enor-
mous therapeutic potential [22-24].
In the present phase I/II trial, the anti-CD3 x anti-
CD20 trAb FBTA05 is applied in combination with DLI
in patients with CD20-positive CLL, low- and high-
grade NHL relapsed or refractory after allo-SCT. The
primary goal of this combined FBTA05/DLI treatment
approach is to further improve an already successful
allogeneic DLI regime for patients with resistant B cell
malignancies who relapsed after allo-SCT [25,26]. In
addition, Riechelmann and co-workers showed that
opsonization of autologous effector cells (i.e. peripheral
blood mononuclear cells) with anti-EpCAM x anti-CD3
trAb catumaxomab led to beneficial results (i.e. toler-
ability, safety and response) in patients with intractablerecurrent head and neck squamous cell carcinomas [27].
Based on these findings and anticipating our own pre-
liminary clinical data from a small pilot study [16], the
planned treatment schedule is designed to enhance the
targeting of tumor cells by allogeneic T lymphocytes
while reducing the risk of undesirable GVHD reactivity
against normal host cells. Hence, FBTA05 may maximize
GVL effects by simultaneously decreasing the incidence
and severity of GVHD as already shown in preclinical
models [28,29]. Of note, these studies about the en-
hancement of graft-versus-tumor effects and the re-
duction of GVHD by means of combined DLI/trAb
application was thoroughly performed upon administra-
tion of C57 splenocytes with or without pretreatment of
anti-EpCAM x anti-CD3 trAb BiLu in (BALB x C57BL/
6) F1 H-2
d/b mice that were previously inoculated with a
lethal dose of B16-EpCAM melanoma cells. Importantly,
the C57 spleen cells were syngeneic to the B16-EpCAM
tumor cells, but haploidentically mismatched to host
cells. Treatment with BiLu protected recipient mice
from the alloreactive C57 splenocytes, as GVHD-related
death was observed in only 20% of mice whereas almost
all mice inoculated with naive C57 splenocytes w/o BiLu
pretreatment died of GVHD [29]. In total 50% of all
treated mice were disease-free in this experimental set-
tings. BiLu treatment w/o cell therapy also had a sub-
stantial anti-tumor effect, as a similar proportion of
treated mice were disease-free under these conditions
[29]. Thus, future trials could also address the feasibility
to pass on DLI in relevant clinical settings. Here, this
clinical study with a combined trAb/DLI treatment
might provide further insights into the capacity of this
therapeutic regime to deplete malignant B cells, activate
the immune system and induce secondary cell-mediated
immunity.
Trial status
The study is currently recruiting patients.
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